Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

Polymyxin combination therapy is increasingly used clinically. However, systematic investigations of such combinations are a relatively recent phenomenon. The emerging pharmacodynamic (PD) and pharmacokinetic (PK) data on CMS/colistin and polymyxin B suggest that caution is required with monotherapy...

Full description

Saved in:
Bibliographic Details
Published in:Infectious diseases and therapy 2015-12, Vol.4 (4), p.391-415
Main Authors: Bergen, Phillip J., Bulman, Zackery P., Landersdorfer, Cornelia B., Smith, Nicholas, Lenhard, Justin R., Bulitta, Jürgen B., Nation, Roger L., Li, Jian, Tsuji, Brian T.
Format: Article
Language:English
Subjects:
Bacteria
Drug therapy
Gram-negative bacteria
Infectious Diseases
Internal Medicine
Medical research
Medicine
Medicine & Public Health
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Polymyxin combination therapy is increasingly used clinically. However, systematic investigations of such combinations are a relatively recent phenomenon. The emerging pharmacodynamic (PD) and pharmacokinetic (PK) data on CMS/colistin and polymyxin B suggest that caution is required with monotherapy. Given this situation, polymyxin combination therapy has been suggested as a possible way to increase bacterial killing and reduce the development of resistance. Considerable in vitro data have been generated in support of this view, particularly recent studies utilizing dynamic models. However, most existing animal data are of poor quality with major shortcomings in study design, while clinical data are generally limited to retrospective analysis and small, low-power, prospective studies. This article provides an overview of clinical and preclinical investigations of CMS/colistin and polymyxin B combination therapy.
ISSN:2193-8229
2193-6382
DOI:10.1007/s40121-015-0093-7